Literature DB >> 8403251

In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries.

S W Lee1, B C Trapnell, J J Rade, R Virmani, D A Dichek.   

Abstract

We studied the ability of adenoviral vectors to achieve gene transfer into injured arteries. A recombinant adenoviral vector expressing a nuclear-targeted beta-galactosidase gene was constructed and infused into balloon-injured rat carotid arteries. Three days after gene transfer, recombinant gene expression was assessed quantitatively by (1) measuring beta-galactosidase antigen and activity in tissue extracts and (2) histochemical staining and counting of cells expressing beta-galactosidase. Exposure of injured carotid arteries to increasing concentrations of the vector (10(8) to 10(10) plaque-forming units per milliliter) resulted in a dose-responsive increase in beta-galactosidase expression, with peak expression of approximately 43 mU or 25 ng beta-galactosidase per vessel. Microscopic examination of histochemically stained arteries demonstrated gene transfer limited to the vascular media; transduced cells were identified immunohistochemically as smooth muscle cells. Counting of both histochemically stained and total nuclei in the media revealed that approximately 30% of the cells in the media of the injured vessels were transduced. Calculations based on both counting cells and on the level of beta-galactosidase expression in tissue extracts suggested the presence of 5000 to 10,000 transduced cells per 10 mm of vessel. Arteries infused with either vehicle only, a control adenoviral vector, or liposomes combined with the vector plasmid contained little or no evidence of beta-galactosidase expression. High levels of in vivo beta-galactosidase expression persisted for at least 7 days after gene transfer but declined significantly by day 14. We conclude that adenoviral vector-mediated gene transfer into the injured rat carotid artery results in efficient gene transfer into the vascular media, with levels of recombinant protein production significantly higher than any previously reported in arterial gene transfer studies. Adenoviral vectors appear to be particularly useful agents for in vivo arterial gene transfer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403251     DOI: 10.1161/01.res.73.5.797

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  23 in total

1.  Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor.

Authors:  B Witzenbichler; Y Kureishi; Z Luo; A Le Roux; D Branellec; K Walsh
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Nonviral gene transfer strategies for the vasculature.

Authors:  Jennifer L Young; David A Dean
Journal:  Microcirculation       Date:  2002-01       Impact factor: 2.628

Review 3.  Cell physiology as a variable in gene transfer to endothelium.

Authors:  Philip L Leopold
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

4.  Novel methods for adenovirus-mediated gene transfer to blood vessels in vivo.

Authors:  H Ooboshi; C D Ríos; D D Heistad
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

5.  Gene transfer to intact mesenteric arteries by electroporation.

Authors:  J B Martin; J L Young; J N Benoit; D A Dean
Journal:  J Vasc Res       Date:  2000 Sep-Oct       Impact factor: 1.934

Review 6.  Current aspects of gene therapy: implications for vascular interventions.

Authors:  F Reifers; J Kreuzer
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

7.  Adenovirus mediated-gene transfer into cardiomyocytes.

Authors:  L A Kirshenbaum
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

8.  Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH(2)-terminal domains.

Authors:  Philip G Massey; Shinji Tanaka; Joshua M Buckler; Bo Jiang; Anton McCourtie; Kun Qian; Clifford Tom; April Stempien-Otero; Shan Wen; Ian Luttrell; Kanchan Chitaley; David A Dichek
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

9.  Protection from reoxygenation injury by inhibition of rac1.

Authors:  K S Kim; K Takeda; R Sethi; J B Pracyk; K Tanaka; Y F Zhou; Z X Yu; V J Ferrans; J T Bruder; I Kovesdi; K Irani; P Goldschmidt-Clermont; T Finkel
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

10.  Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth.

Authors:  Marten Falkenberg; Clifford Tom; Mary Beth DeYoung; Shan Wen; Ruth Linnemann; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.